(-)(R)-1-Chlor-2,3,3-Trimethylbutan | 54677-13-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 英文名称: (-)(R)-1-Chlor-2,3,3-Trimethylbutan
• 英文别名: 1-Chloro-2,3,3-trimethylbutane
• CAS: 54677-13-3
• 化学式: C₇H₁₅Cl
• 分子量: 134.649
• InChiKey: ZUIGQNGRMZCADY-UHFFFAOYSA-N

物化性质

• 沸点：
  133.2±8.0 °C(Predicted)
• 密度：
  0.863±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  (-)(R)-1-Chlor-2,3,3-Trimethylbutan 生成 2,2,3,5-四甲基庚烷
  参考文献：
  名称：

  Conformational rigidity in aliphatic paraffins. Synthesis and determination of absolute configuration of (3S,5S) and (3R,5S)-2,2,3,5-tetramethylheptane

  摘要：

  DOI：

  10.1021/ja00987a081
• 作为产物：
  描述：

  2,3,3-trimethylbutan-1-ol 在 trichloroisocyanuric acid 作用下， 以 二氯甲烷 为溶剂， 反应 0.1h， 生成 (-)(R)-1-Chlor-2,3,3-Trimethylbutan
  参考文献：
  名称：

  Trichloroisocynuric Acid/DMF as Efficient Reagent for Chlorodehydration of Alcohols Under Conventional and Ultrasonic Conditions

  摘要：

  A new and efficient method for the chlorodehydration of alcohols utilizing TCCA/DMF is described. Various alcohols can be converted smoothly into their corresponding alkyl chlorides in high yields under mild conditions with short reaction times.

  DOI：

  10.1080/15533174.2013.819896

文献信息

• CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20200062727A1

  公开（公告）日：2020-02-27

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明揭示了化合物的结构式（I），及其在药学上可接受的盐，这些化合物抑制凋亡信号调节激酶1（ASK-1），与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病有关。本发明还涉及包含上述化合物的药物组合物，用于治疗患有ASK-1相关疾病的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的ASK-1相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎疾病（NASH）。
• Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10968199B2

  公开（公告）日：2021-04-06

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了式 (I) 的化合物、 及其药学上可接受的盐类，它们能抑制与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾病、心血管疾病相关的凋亡信号调节激酶 1 (ASK-1)。本发明进一步涉及包含上述化合物的药物组合物，用于给患有 ASK-1 相关疾病的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 ASK-1 相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）。
• NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF
  申请人：S&T Global Inc.

  公开号：US20190151403A1

  公开（公告）日：2019-05-23

  A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.
• US9938236B2
  申请人：——

  公开号：US9938236B2

  公开（公告）日：2018-04-10